Taltz(ixekizumab)
Taltz (ixekizumab) is an antibody pharmaceutical. Ixekizumab was first approved as Taltz on 2016-03-22. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. The pharmaceutical is active against interleukin-17A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Taltz
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| taltz | Biologic Licensing Application | 2024-11-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 1 | 14 | 5 | 1 | 23 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | 1 | 4 | 4 | 1 | 12 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | — | 5 | 4 | 1 | 10 |
| Spondylitis | D013166 | — | M46.9 | — | — | 7 | 1 | — | 8 |
| Spondylarthritis | D025241 | — | — | — | — | 6 | 1 | — | 7 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 1 | — | 1 | — | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 2 | 2 | — | 4 |
| Overweight | D050177 | — | E66.3 | — | — | 2 | 2 | — | 4 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | 1 | — | 1 |
| Intermediate uveitis | D015867 | EFO_1000986 | — | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Axial spondyloarthritis | D000089183 | — | — | — | — | 5 | — | — | 5 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | 2 | — | — | 2 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | — | — | 1 | — | — | 1 |
| Enthesopathy | D000070676 | — | M77.9 | — | — | 1 | — | — | 1 |
| Non-radiographic axial spondyloarthritis | D000089202 | — | M45.A | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pityriasis rubra pilaris | D010916 | — | L44.0 | — | 1 | — | — | — | 1 |
| Exfoliative dermatitis | D003873 | — | L26 | — | 1 | — | — | — | 1 |
| Pityriasis | D010915 | — | — | — | 1 | — | — | — | 1 |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 1 | — | — | — | 1 |
| Pyoderma | D011711 | — | L08.0 | — | 1 | — | — | — | 1 |
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ixekizumab |
| INN | ixekizumab |
| Description | Ixekizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >6NOV:A,C|Fab Heavy Chain
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAY
MELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
>6NOV:B,D|Fab Light Chain
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKI
SRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 6NOU, 6NOV |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743034 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11569 |
| UNII ID | BTY153760O (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Taltz – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,331 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,079 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use